

CV

Doc. dr sc. med. spec. Snežana Mugoša

Direktorica Instituta za lijekove i medicinska sredstva

Docent na Medicinskom fakultetu u Podgorici



Lične informacije

Datum rođenja: 14.02.1979.

Mjesto rođenja: Nikšić, Crna Gora

Email adresa: snezana.mugosa@cinmed.me

Radno iskustvo

Institut za lijekove i medicinska sredstva – CinMED

Direktorica 2022 –

Zamjenica direktora 2021 – 2022.

Rukovodilac Odjeljenja za klinička ispitivanja lijekova i procjenu efikasnosti i bezbjednosti lijeka 2012 – 2022.

Clinical Reasearch Academy (CRA), Belgrade

Predavač 2013 –

Medicinski fakultet Univerziteta Crne Gore

Docent za oblast Klinička farmacija i farmakoterapija

Farmakološka grupa medicinskih predmeta 2021 –

Saradnik u nastavi na farmakološkoj grupi predmeta 2004 – 2021.

Centar za kardiologiju, Klinički centar Crne Gore

Specijalista interne medicine 2011 – 2012.

Specijalizant interne medicine 2006 – 2011.

Dom zdravlja Podgorica, Centar za hitnu medicinsku pomoć

Ljekar u Centru 2004 – 2005.

Obrazovanje

Uža specijalizacija iz kliničke farmakologije i farmakoterapije, Medicinski fakultet Univerziteta u Beogradu, u trajanju od jedne godine. Zvanje užeg specijaliste kliničke farmakologije i farmakoterapije stekla 2025. godine, položivši završni ispit sa ocjenom A.

Doktorske studije, Medicinski fakultet Univerziteta Crne Gore, Podgorica, u trajanju od tri godine. Doktorska disertacija iz oblasti kliničke farmakologije i terapije pod nazivom „*Analiza faktora rizika za nastanak neželjenih dejstava lijekova kod kardioloških bolesnika*“ odbranjena 2015. godine sa ocjenom A.

Specijalizacija iz interne medicine, Medicinski fakultet Univerziteta u Beogradu, u trajanju od četiri godine. Zvanje specijaliste interne medicine stekla 2011. godine, položivši specijalistički ispit sa ocjenom odličan (5).

Magistarske studije iz kliničke farmakologije i terapije, Medicinski fakultet Univerziteta u Beogradu, u trajanju od dvije godine. Magistarska teza pod nazivom „*Intenzivno praćenje neželjenih reakcija na lijekove kod hospitalizovanih bolesnika na kardiološkom odjeljenju: pilot projekat*“ odbranjena 2009. godine sa ocjenom A.

Medicinski fakultet Univerziteta Crne Gore, Podgorica – diplomirala 2004. godine sa prosječnom ocjenom 9,69, najvišom u generaciji.

Gimnazija „Stojan Cerović“, Nikšić – proglašena učenikom generacije.

Osnovna škola „Olga Golović“, Nikšić – proglašena učenikom generacije.

Profesionalne kvalifikacije i sertifikati

Dugogodišnje iskustvo na stručnim i rukovodećim poslovima u oblasti regulative lijekova i medicinskih sredstava.

Stručna i naučnoistraživačka usavršavanja u oblastima kliničke farmakologije, farmakoterapije, farmakovigilance, farmakoepidemiologije, farmakogenetike, kliničkih ispitivanja i potrošnje lijekova.

Sertifikat Evropske agencije za lijekove za inspektora dobre kliničke prakse.

Usavršavanje iz oblasti izvođenja eksperimenata na eksperimentalnim životinjama, Medicinski fakultet Univerziteta u Beogradu.

Položen stručni ispit za rad u državnim organima.

Međunarodni projekti

Rukovodilac Erasmus+ projekta Development and Implementation of Metacognitive Problem-Based Modules in Blended Learning Courses in Medical Sciences (ProBLEMS), u okviru programa Capacity Building in Higher Education (CBHE) (2023–2026).

Istraživač u međunarodnom projektu COST Action CA24165 – Network for Cardiovascular Pharmacogenomics and Precision Medicine (CardioPharmaGENET) (2025–2029).

Član Upravnog odbora međunarodnog projekta COST Action CA23154 – Environmental Impact of Anthelmintics in Livestock and Alternatives to Minimize Their Use (ENVIRANT) (2024–2028).

Član Upravnog odbora i istraživač u međunarodnom projektu COST Action CA18217 – European Network for Optimization of Veterinary Antimicrobial Treatment (ENOVAT) (2019–2023).

Lider EU Twinning projekta sa Hrvatskom agencijom za lijekove i medicinske proizvode (HALMED), pod nazivom „Podrška Institutu za lijekove i medicinska sredstva Crne Gore“ (2021–2022).

Nacionalni projekti

Učesnik u nacionalnom naučnoistraživačkom projektu NANOTIN – New Triphenyltin(IV) Complexes with Mixed Ligands Incorporated into Mesoporous Silica Nanoparticles: Synthesis, Characterization and Evaluation of Biological Activity and Antitumour Potential, Ministarstvo prosvjete, nauke i inovacija Crne Gore/CInMED (2026–2028).

Istraživač u nacionalnom naučnoistraživačkom projektu „Analiza faktora rizika za nastanak neželjenih dejstava lijekova kod kardioloških bolesnika“, čiji je nosilac bila Agencija za lijekove i medicinska sredstva Crne Gore (2013–2015).

Članstva u stručnim i međunarodnim udruženjima

Član Ljekarske komore Crne Gore.

Član Evropskog udruženja za kliničku farmakologiju i terapiju (EACPT).

Član Udruženja profesionalaca u oblasti kliničkih ispitivanja (ACRP).

Član Udruženja za unapređivanje kliničkih ispitivanja Srbije (KLINIS).

Član Međunarodnog društva za farmakoekonomiju i istraživanje ishoda (ISPOR).

Član Međunarodnog društva za farmakovigilancu (ISoP).

Član Crnogorskog društva za borbu protiv raka.

Član Udruženja za zaštitu životinja Crne Gore.

Strani jezici i digitalne vještine

Engleski jezik – napredno znanje (C1 nivo)

Napredne digitalne vještine, uključujući ECDL (*European Computer Driving Licence*) sertifikat.

Naučno - istraživački radovi objavljeni u cjelosti

1. Pantić IV, **Mugoša S**. Artificial intelligence strategies based on random forests for detection of AI-generated content in public health. *Public Health*. 2025;242:382–7.
doi:10.1016/j.puhe.2025.03.030.
2. Vojinović A, Medarević Đ, Stanojević G, Mirković D, **Mugoša S**, Adamov I, et al. Development and evaluation of 3D-printed losartan potassium tablets using semi-solid extrusion: the effect of geometry, drug loading and superdisintegrant. *Pharmaceuticals (Basel)*. 2025;18(10):1504.
doi:10.3390/ph18101504.
3. Kovačević Z, Tomanić D, Šarić L, **Mugoša S**, Budinski K, Novaković D, et al. Exploring pet owners' attitudes toward compounded and human approved medicines: a questionnaire based pilot study. *Vet Res Commun*. 2025;49(2):64.
doi:10.1007/s11259-024-10635-2.
4. **Mugoša S**, Tomanić D, Ibrić S, Boljević G, Kovačević Z. Exploring the potential of integrating 3D printing in veterinary medicine to address antimicrobial resistance: a review. *Farmacia*. 2025;73(3):525–534.
doi:10.31925/farmacia.2025.3.1.
5. Vukićević V, **Mugoša S**, Stanojević G, Vezmar Kovačević S. How effective is the implementation of the valproate pregnancy prevention programme in Montenegro? A 7-year national retrospective study. *Ther Adv Drug Saf*. 2025;16:20420986251360888.
doi:10.1177/20420986251360888.
6. **Mugoša S**, Krivokapić M, Tomanić D, Šarić L, Kovačević Z. A decade of antibacterial drug consumption for systemic use in Montenegro (2014–2023): trends, patterns, and AWaRe classification insights. *Vojnosanit Pregl*. 2025;82(10):653–661.
doi:10.2298/VSP250424068M
7. **Mugoša S**, Meštrović A, Vukićević V, Žugić M, Rouse MJ. SMART Pharmacist—the impact of education on improving pharmacists' participation in monitoring the safety of medicine use in Montenegro. *Pharmacy (Basel)*. 2025;13(2):57.
doi:10.3390/pharmacy13020057.
8. Rašković A, Steinbach M, **Mugoša S**, Baljak J, Prodanović D, Sabo S, et al. Patient information leaflets: how do patients comprehend and understand drug information? *Arch Pharm Pract*. 2024;15(1):7–11.
doi:10.51847/n2jlaSAlbK.
9. Bukumirić Z, Stanisavljević D, Milić N, Ćirković A, Milin-Lazović J, **Mugoša S**, et al. Assessing psychometric properties of the Serbian version of the Metacognitive Awareness Inventory (MAI). *Srp Med Cas Lek Komore*. 2024;5(4):543–554.
doi:10.5937/smcl5-55246.
10. Kovačević Z, Mihajlović J, **Mugoša S**, Horvat O, Tomanić D, Kladar N, et al. Pharmacoeconomic analysis of the different therapeutic approaches in control of bovine mastitis: phytotherapy and antimicrobial treatment. *Antibiotics (Basel)*. 2023;12(1):11.
doi: 10.3390/antibiotics12010011
11. **Mugoša S**, Vračar V, Tešin N, Mitrović J, Tomanić D, Kovačević Z. Antimicrobial veterinary drug sale pattern in correlation with critically important antimicrobials for human use: a five-year study in Montenegro. *Acta Microbiol Immunol Hung*. 2023;70(4):340–347.
doi:10.1556/030.2023.02116.
12. Kovačević Z, **Mugoša S**, Lalić-Popović M, Stojanović S, Tešin N, Marić D, et al. Veterinary compounding: the impact of different gelling agents on the rheological characteristics and release kinetics from meloxicam oral gels in the treatment of cats. *Vet Arhiv*. 2023;93(6):695–708.
doi:10.24099/vet.arhiv.2279.

13. Kočović D, **Mugoša S**, Shova S, Tomić Z, Jaćimović Ž. Crystal structure of 3-(4-bromophenyl)-5-methyl-1H-pyrazole, C₁₀H₉BrN₂. *Z Kristallogr New Cryst Struct*. 2023;238(5):863–865.
doi:10.1515/ncrs-2023-0242.
14. Adamov I, Stanojević G, Kočović D, **Mugoša S**, Grujić B, Ibrić S. Selective laser sintering (SLS) 3D printing process: influence of model design on the properties of zolpidem tartrate tablets. *Maced Pharm Bull*. 2023;69(Suppl 1):133–134.
doi:10.33320/maced.pharm.bull.2023.69.03.065.
15. Kočović D, **Mugoša S**. Falsifikovani lijekovi i farmaceutski kriminal. *Crnogorska revija za bezbjednost*. 2023;(2):71–84.
16. Šahman-Zaimović M, **Mugoša S**. Comparative analysis of the use of non-steroidal anti-inflammatory drugs in Montenegro, Finland and Croatia in the period 2010–2019. *Eur Rev Med Pharmacol Sci*. 2022;26(13):4789–4797.
doi:10.26355/eurrev_202207_29204.
17. **Mugosa S**, Radosavljevic I, Sahman M, Djordjevic N, Todorovic Z. Risk factors for adverse drug reactions associated with clopidogrel therapy. *Open Med (Wars)*. 2022;17(1):694–701.
doi: 10.1515/med-2021-0371
18. Antunović M, Lopičić M, Vučković L, Raonić J, **Mugoša S**. Prevalence and clinical implications of the HPV16 infection in oral cancer in Montenegro: evidence to support the immunization program. *Acta Microbiol Immunol Hung*. 2022;69(3):241–246.
doi:10.1556/030.2022.01794.
19. **Mugoša S**, Glušica A. Clinical trial challenges: impact of the new clinical trial regulation on the conduct of clinical trials. *Vojnosanit Pregl*. 2022;79(9):918–923.
doi:10.2298/VSP200316061M.
20. Mladenović K, Dragojević-Simić V, **Mugoša S**, Rančić N. Costs and consumption of analgesics, with special reference to opiates in Serbia and Montenegro from 2015 to 2019. *Vojnosanit Pregl*. 2022;79(12):1239–1247.
doi:10.2298/VSP210606002M.
21. **Mugoša S**, Kovačević A, Tomanić D, Kovačević Z. Trends of veterinary antibiotic use in Montenegro. In: Ružić Z, Galić I, editors. *Antimicrobial Resistance in Veterinary Medicine – Current State and Perspectives. Proceedings of the Conference, 21–23 June 2022, Novi Sad. University of Novi Sad, Faculty of Agriculture*; 2022:63–67.
22. Sahman M, **Mugosa S**, Rancic N. Utilization of mycophenolic acid, azathioprine, tacrolimus, cyclosporin, sirolimus, and everolimus: multinational study. *Front Public Health*. 2021;9:671316.
doi: 10.3389/fpubh.2021.671316
23. Janković SM, Bogavac-Stanojević N, Mikulić I, Izetbegović S, Ilićević I, **Mugosa S**, et al. A questionnaire for rating health-related quality of life. *Zdr Varst*. 2021;60(4):260–268.
doi:10.2478/sjph-2021-0035.
24. **Mugoša S**, Todorović Z, Cukić J, Šahman-Zaimović M, Đorđević N. ABCB1 polymorphism in clopidogrel-treated Montenegrin patients. *Open Life Sci* 2021;16(1):142–149.
<https://doi.org/10.1515/biol-2021-0017>
25. **Mugoša S**, Džamić Z, Šahman – Zaimović M, Lukovac-Janjić N. Adverse drug reactions associated with sunitinib therapy: characteristics and risk factors. *Vojnosanit Pregl* 2021; 77(4): 456–461.
<https://doi.org/10.2298/VSP201109145M>
26. **Mugoša S**, Stanković M, Turković N, Šahman – Zaimović M, Bešović Ž, Drljević M. Pharmacovigilance as an imperative of modern medicine. *Vojnosanit Pregl* 2017; 74(2): 167–172.
<https://doi.org/10.2298/VSP150428167M>

27. **Mugoša S**, Đorđević N, Đukanović N, Protić D, Bukumirić Z, Radosavljević I, Bošković A, Todorović Z. Factors affecting the development of adverse drug reactions to β -blockers in hospitalized cardiac patient population. *Patient Preference Adherence* 2016; 10:1461-9.
<https://doi.org/10.2147/PPA.S108579>
28. **Mugoša S**, Đorđević N, Bukumirić Z, Đukanović N, Cukić J, Radosavljević I, Baskić D, Protić D, Zdravković M, Todorović Z. PREDICT score and CYP2C19 polymorphism independently predict lack of efficacy of clopidogrel in cardiology patients. *Clin Exp Pharmacol Physiol* 2016; 43(3): 379-81.
<https://doi.org/10.1111/1440-1681.12531>
29. Šoškić M, Dabanović V, Čukić A, **Mugoša S**. Benzodiazepine use among the general population in the municipality of Berane, Montenegro. *Rational therapy* 2016; 8(2): 9-14.
<https://doi.org/10.5937/racter8-10932>
30. **Mugoša S**. Farmakogenetika – budućnost farmakoterapije. *Bilten Farmaceutске komore Crne Gore* 2016; 5:29-31.
31. **Mugoša S**, Bukumirić Z, Kovačević A, Bošković A, Protić D, Todorović Z. Adverse drug reactions in hospitalised cardiac patients: characteristics and risk factors. *Vojnosanit Pregl* 2015; 72(11): 975–981.
<https://doi.org/10.2298/VSP140710104M>
32. **Mugoša S**, Kučević B, Rolevski M, Bukumirić Z, Bešović Ž, Drljević M. Public Awareness and Perception of Clinical Trials in Montenegro. *Hospital Pharmacology*. 2015; 2(3): 317-321.
<https://doi.org/10.5937/hpimj1503317M>
33. **Mugoša S**, Stanković M, Turković N, Šahman – Zaimović M. Medical Dictionary MedDRA - used in over 60 countries, among which is Montenegro. *Hospital Pharmacology* 2015; 2(2): 266-271.
<https://doi.org/10.5937/hpimj1502266M>
34. **Mugoša S**, Stanković M, Turković N, Šahman – Zaimović M, Bešović Ž, Drljević M. Pharmacovigilance: empowering healthcare professionals. *Hospital Pharmacology* 2015; 2(2): 255-260.
<https://doi.org/10.5937/hpimj1502255M>
35. Protić D, Baltić S, Vujašinovic Stupar N, Pavlov-Dolijanović S, **Mugoša S**, Todorović Z. A case of myositis with immunological background associated with statin use. *Cent Eur J Med* 2014; 9(5): 619-24.
<https://doi.org/10.2478/s11536-013-0313-z>
36. **Mugoša S**, Todorović Z, Bošković A. Frequency of adverse drug reactions in hospitalized patients in Cardiology center of Clinical centre of Montenegro. *Pharmaca Serbica* 2011, 3(1-2): 7-11.
37. **Mugoša S**, Duborija-Kovačević N. Bolnička upotreba lijekova na četiri hirurške klinike Kliničkog centra Crne Gore. *Med zap* 2006 (61): 121-31.

Saopštenja na naučnim skupovima objavljena u vidu sažetaka

38. **Mugoša S**, Babović T, Boljević G-Stanojević, Mićović T, Novaković N. New regulations in Montenegro – new rules in the fight against antimicrobial resistance. In: 5th International Conference Antimicrobial Resistance – Current State and Perspectives: From Science to Practice. Book of Abstracts, 28–30 May 2026, Novi Sad. University of Novi Sad, Faculty of Agriculture; 2026:24.
39. **Mugoša S**, Čizmović L, Tomanić D, Kovačević Z. Antimicrobial consumption in Montenegro from 2009 to 2024. In: 4th International Conference Antimicrobial Resistance – Current State and Perspectives. Book of Abstracts, 19–21 June 2025, Novi Sad. University of Novi Sad, Faculty of Agriculture; 2025:6.
40. Vukicevic V, Vujovic S, Cizmovic L, Stanojevic G, **Mugosa S**, Vezmar Kovacevic S. The awareness, knowledge and behaviour regarding valproate pregnancy prevention programme – questionnaire survey among patients in Montenegro [abstract]. In: 24th ISoP Annual Meeting “Pharmacovigilance: Back to the Future”; 2025 Oct 24–27; Cairo, Egypt. Drug Saf. 2025;48:1433–1660.
41. Vukicevic V, **Mugosa S**, Boljevic Stanojevic S, Vezmar Kovacevic S. Effects of the regulatory measures on valproate prescription in Montenegro – a seven-year national retrospective study [abstract]. In: 24th ISoP Annual Meeting “Pharmacovigilance: Back to the Future”; 2025 Oct 24–27; Cairo, Egypt. Drug Saf. 2025;48:1433–1660.
42. **Mugoša S**, Čizmović L, Tomanić D, Kovačević Z. Antimicrobial consumption in Montenegro from 2009 to 2022. In: 3rd International Conference Antimicrobial Resistance – Current State and Perspectives. Book of Abstracts, 16–18 May 2024, Novi Sad. University of Novi Sad, Faculty of Agriculture; 2024:25.
43. Vukicevic V, **Mugosa S**, Vezmar Kovacevic S. Are men and women equal when it comes to valproates – analysis of prescribing practice in Montenegro [abstract]. In: 23rd ISoP Annual Meeting “Global Perspectives on Pharmacovigilance in the Digital Age and Advanced Therapeutics”; 2024 Oct 1–5; Montreal, Canada. Drug Saf. 2024;47:1307–1439.
44. **Mugoša S**, Babović T, Boljević G, Tomanić D, Tešin N. Critically important antimicrobial from human practice trend of use in veterinary medicine in Montenegro. In: 2nd International Conference Antimicrobial Resistance in Veterinary Medicine – Current State and Perspectives. Book of Abstracts, 22–24 June 2023, Novi Sad. University of Novi Sad, Faculty of Agriculture; 2023:56–57.
45. **Mugosa S**. Pharmacogenetic factors affecting adverse drug reactions of β -blockers [abstract]. In: 22nd ISoP Annual Meeting “Putting Patients First in Pharmacovigilance: International Perspectives from Global South”; 2023 Nov 6–9; Bali, Indonesia. Drug Saf. 2023;46:1173–1295.
46. **Mugoša S**. Clinical trials challenges – Good Clinical Practice Guidelines (abstract). Montenegrin international medical summit, 3-6. oktobar 2019, Podgorica, Crna Gora. Abstrakt objavljen u: Abstract book 2019, p.44.
47. **Mugoša S**, Bešović Ž, Šahman-Zaimović M, Drljević M. Uticaj nove Regulative Evropske unije na sprovođenje kliničkih ispitivanja u regionu (The impact of new European Union Regulation on conducting clinical trials in the region) (abstract). 14. Kongres farmakologa i 4. Kongres kliničke farmakologije Srbije sa međunarodnim učešćem, 18-21. septembar 2019, Novi Sad, Srbija. Abstrakt objavljen u: Abstract book 2019, p.128-129.
48. **Mugoša S**, Todorović Z, Đorđević N. Impact of genetic and non-genetic factors on clopidogrel efficacy (abstract). International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2018: New Perspectives for Improving 21st Century Health Systems, 10-14. novembar 2018, Barselona, Španija. Abstrakt objavljen u časopisu sa SCI liste: Value in Health 2018 Oct 01; 21(Suppl 3):S96.
49. Kucevic B, Rolevski M, Sahman-Zaimovic M, Besovic Z, **Mugosa S**. Promoting public awareness of clinical trials in Montenegro (abstract). 12th Congress of the European Association for Clinical Pharmacology and Therapeutics, 27-30. jun 2015, Madrid, Španija. Abstrakt objavljen u časopisu sa SCI liste: Clinical Therapeutics 2015 Aug; 37(8S): e.39.
50. Turkovć N, Stanković M, Bešović Ž, Čizmović L, **Mugoša S**. Važna uloga farmaceuta u prijavljivanju neželjenih dejstava lijekova (abstract). II Kongres farmaceuta Crne Gore sa međunarodnim učešćem, 28-31. maj 2015, Budva, Crna Gora. Abstrakt objavljen u: Zbornik sažetaka 2015, p.188.

51. Šarkinović E, Bešović Ž, Drljević M, Šahman-Zaimović M, **Mugoša S**. Regulatorni osvrt na biološki slične lijekove (abstract). II Kongres farmaceuta Crne Gore sa međunarodnim učešćem, 28-31. maj 2015, Budva, Crna Gora. Abstrakt objavljen u: Zbornik sažetaka 2015, p.179.
52. Stanković M, Turković N, Čizmović L, Bešović Ž, **Mugoša S**. Promjene u potrošnji diklofenaka kao rezultat komunikacije prema zdravstvenim radnicima (abstract). II Kongres farmaceuta Crne Gore sa međunarodnim učešćem, 28-31. maj 2015, Budva, Crna Gora. Abstrakt objavljen u: Zbornik sažetaka 2015, p.177-178.
53. **Mugoša S**, Todorović Z, Šahman-Zaimović M, Drljević M, Đorđević N. Polimorfizam CYP2D6 – faktor rizika za nastanak neželjenih dejstava beta blokatora (abstract). II Kongres farmaceuta Crne Gore sa međunarodnim učešćem, 28-31. maj 2015, Budva, Crna Gora. Abstrakt objavljen u: Zbornik sažetaka 2015, p.156-157.
54. Kučević B, Rolevski M, Šahman-Zaimović M, Bešović Ž, **Mugoša S**. Stavovi i informisanost opšte javnosti o kliničkim ispitivanjima (abstract). II Kongres farmaceuta Crne Gore sa međunarodnim učešćem, 28-31. maj 2015, Budva, Crna Gora. Abstrakt objavljen u: Zbornik sažetaka 2015, p.139-140.
55. Mikov M, Goločorbin-Kon S, **Mugoša S**. Značaj pretkliničke i kliničke farmakovigilance za farmakoterapiju (abstract). II Kongres farmaceuta Crne Gore sa međunarodnim učešćem, 28-31. maj 2015, Budva, Crna Gora. Abstrakt objavljen u: Zbornik sažetaka 2015, p.60.
56. **Mugosa S**, Bukumiric Z, Protic D, Todorovic Z. Influence of pharmacological education on awareness of the risk of adverse drug reactions (abstract). 11th Conference of the European Association for Clinical Pharmacology and Therapeutics, 28-31. avgust 2013, Ženeva, Švajcarska. Abstrakt objavljen u časopisu sa SCI liste: Clinical Therapeutics 2013 Aug; 35(8S): e.26.
57. **Mugoša S**, Todorović Z, Šahman-Zaimović M. Adverse drug reactions and polypharmacy in cardiac patients (abstract). 18th Scientific Symposium of the Austrian Pharmacological Society (APHAR), 20-21. septembar 2012, Grac, Austrija. Abstrakt objavljen u časopisu sa SCI liste: BMC Pharmacology and Toxicology 2012 Sep 17; 13(Suppl 1):A39.